News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II (World)
ERYtech Pharma Announces 2016 Financial Calendar 2/8/2016
Can-Fite BioPharma (CFBI) To Present At BIO CEO & Investor Conference In New York City On February 8, 2016 2/5/2016
Nordic Nanovector To Present At The Swiss-Scandinavian Bio-Business Seminar On 10 February 2016 2/5/2016
ERYtech Pharma To Present At Upcoming Investor Conferences 2/4/2016
Takeda (TKPYY) Release: FDA Psychopharmacologic Drug Advisory Committee Supports the Effectiveness of Brintellix (vortioxetine) in Treating Certain Aspects of Cognitive Dysfunction in Major Depressive Disorder (MDD) 2/4/2016
Kamada Ltd. (KMDA) Reports 2015 Fourth Quarter And Full Year Financial Results 2/2/2016
Transition Therapeutics (TTH.TO) Announces Top Line Phase 2 Clinical Study Results Of Diabetes Drug Candidate TT401 2/1/2016
BioLineRx Ltd. To Present At 2016 BIO CEO & Investor Conference In New York On February 8 2/1/2016
Medivir (MVRBF) Initiates Phase IIa Study Of MIV-711 In Knee Osteoarthritis 1/28/2016
Genticel's HPV Candidate Did Not Meet Primary Endpoint in Phase II Study 1/27/2016
Galapagos (GLPG.BR) Shuts Down Ulcerative Colitis Program After Drug Failed to Prove Efficacy in Trial 1/26/2016
Can-Fite BioPharma (CFBI) CEO Dr. Pnina Fishman To Chair Scientific Session At The 2016 Purinergic Signaling And Cancer Immunotherapy Conference In Vancouver On January 26, 2016 1/25/2016
ViroMed Publishes Results From Critical Limb Ischemia (CLI) Phase II Clinical Study 1/22/2016
Summit Therapeutics Receives Regulatory Approval To Initiate Phaseout DMD, A Phase II Clinical Trial Of SMT C1100 In Patients With DMD 1/21/2016
OncoGenex (OGXI) Sinks as Lung Cancer Drug Apatorsem Flunks Phase II Study 1/21/2016
BrainStorm Cell's Stem Cell Treatment Stops Disease Progression in 87% of ALS Patients in Phase II Study 1/12/2016
BrainStorm Cell To Conduct Phase 2 Multi-Dose Nurown Trial In ALS At Hadassah Medical Center 1/11/2016
Roche (RHHBY) Encouraged by Mid-Stage Atezolizumab Bladder Cancer Data 1/8/2016
Apogenix Receives First Milestone Payment From CANbridge Licensing Agreement And Signs Amendment To Include Taiwan 1/7/2016
Jubilant Biosys And Sanofi Deutschland Gmbh Enter Into A Strategic Alliance Focusing On Metabolic Disorders Therapeutic Area 1/7/2016
DS Biopharma Announces Positive Top-Line Phase Ila Trial Results For DS107 As An Oral Treatment For Moderate To Severe Atopic Dermatitis 1/7/2016
Vtesse, Inc. Announces FDA's Granting Of Breakthrough Therapy Designation For VTS-270 In Niemann-Pick Type C1 Disease 1/6/2016
ERYtech Pharma Announces Third DSMB Safety Review And Continuation Of Its Phase IIb Study In Acute Myeloid Leukemia 1/6/2016
Rhythm And Camurus Announce License Agreement For Extended Release Fluidcrystal Setmelanotide 1/5/2016
Galmed Pharmaceuticals To Present At The Biotech Showcase 1/5/2016
BioLineRx Ltd. To Present At Biotech Showcase 2016 Conference In San Francisco 1/4/2016
NeuroDerm (NDRM) Announces Start Of Patient Enrollment In Phase II Trial Of ND0612H For Advanced Parkinson’s Disease 12/30/2015
TWi Biotechnology Inc. Reports Positive Interim Results From AC-201 CR Phase 2 Proof-Of-Concept Study In Gout Patients 12/28/2015
TRANSGENE (ENX:TNG) Announces Publication In "The Lancet Oncology" Of Phase 2b TIME Trial Results With TG4010 Immunotherapy In Non-Small Cell Lung Cancer 12/23/2015
CSL Behring Submits Marketing Authorization Application To The European Medicines Agency For RViii-SingleChain For Patients With Hemophilia A 12/22/2015
Hemostemix Poised To Expand Phase-2 Clinical Trial Of Lead Product ACP-01 To The United States 12/22/2015
ExCellThera Announces Initiation Of Clinical Trial For Cancer Patients 12/21/2015
Can-Fite BioPharma (CFBI)'s CF101 Granted Patent In Japan For Intraocular Pressure A Key Cause Of Glaucoma 12/17/2015
OphthaliX Inc. Announces CF101 Is Granted Patent In Japan For Intraocular Pressure A Key Cause Of Glaucoma 12/17/2015
Addex Therapeutics (ADXN.SW) Reports Statistically Significant Positive Interim Data For Dipraglurant In Healthy Volunteer mGlu5 Receptor Occupancy Trial 12/17/2015
Yisheng Biopharma And The United States Army Medical Research Institute Of Infectious Diseases Announce Collaboration On New Vaccine Against Ebola Virus 12/14/2015
Poxel Announces Imeglimin Phase 2b Initiation In Japan 12/14/2015
Bayer (BAY) Looks to Become Player in Oncology Treatments 12/14/2015
Novartis AG (NVS)’s Experimental Therapy Wipes Out Blood Cancer in 93 Percent of Patients 12/11/2015
Novartis AG (NVS)'s Copycat Works Just as Well as Amgen (AMGN)'s Neulasta 12/8/2015
Can-Fite BioPharma (CFBI) Subsidiary, OphthaliX, Announces Completion Of Patient Enrollment In Phase II Glaucoma Study For CF101 12/7/2015
OphthaliX Announces Completion Of Patient Enrollment In Phase II Glaucoma Study For CF101 12/7/2015
New Clinical Data On MorphoSys AG’s Blood Cancer Drug Candidate MOR208 In NHL And CLL Presented At American Society of Hematology Annual Meeting 12/7/2015
Shares Jump as Foamix Pharma (FOMX)'s FDX104 Shows Efficacy in Phase II Study 12/3/2015
Acacia Pharma: Dr Patrick Vink To Succeed Ian Kent As Non-Executive Chairman 12/3/2015
NovoCure Release: Preliminary Phase 2 Data Demonstrate Tumor Treating Fields Is Safe In Patients With Brain Metastases Originating From Non-Small Cell Lung Cancer 12/2/2015
ProMetic BioSciences, Inc. Confirms PBI-4050's Efficacy In Patients Suffering From Type 2 Diabetes And Metabolic Syndrome 12/1/2015
Galmed Pharmaceuticals Announces FDA Clearance Of IND Of Aramachol For The Treatment Of Patients With HIV-Associated Lipodystrophy And Nonalcoholic Fatty Liver Disease 12/1/2015
XTL Biopharmaceuticals Ltd. (XTLB) Reports Third Quarter 2015 Results and Confirms Intention to Start Lupus Trial In 2016 12/1/2015
BrainStorm Cell Awarded Additional $735,000 Non-Dilutive Grant For 2015 From Israel's Office Of The Chief Scientist 11/30/2015
Otic Pharma Appoints Keith A. Katkin As Chairman Of The Board Of Directors 11/30/2015
SELLAS Life Sciences Reports Positive WT1 Cancer Vaccine Clinical Results In Mesothelioma And Acute Myeloid Leukemia (AML) Patients At The Annual International WT1 Conference 11/30/2015
Can-Fite BioPharma (CFBI) Reports Financial Results For Nine Months Ended September 30, 2015 11/30/2015
Oramed (ORMP) Signs Up To $50 Million Licensing And Investment Agreements For Oral Insulin Capsule In China 11/30/2015
Allergy Therapeutics plc Completion Of Patient Enrolment In PQBirch204 Phase II Study 11/30/2015
ESSA Pharma Announces Enrollment Of First Patient In Phase 1/2 Trial 11/25/2015
iCo Therapeutics Inc. Announces Third Quarter 2015 Financial Results 11/25/2015
BioLineRx Ltd. To Host Investor Breakfast In New York On December 3, 2015 11/25/2015
ProMetic Life Sciences Inc. (PFSCF.PK) To Present At The Piper Jaffray 27th Annual Healthcare Conference In New York On Tuesday December 1, 2015 11/24/2015
Qu Biologics Completes Enrollment Of Randomized Clinical Trial In Crohn's Disease 11/24/2015
Generon (Shanghai) Corporation Ltd. Collaborating With Mayo Clinic To Initiate A Phase IIa Study With F-652, A First-In-Class Biologic, To Treat Patients With Alcoholic Hepatitis 11/23/2015
BioLineRx Ltd. Announces Initiation Of Phase 1/2 Trial For Novel Treatment In Two Bone Marrow Failure Conditions 11/23/2015
Poxel Presents New Data On Imeglimin And PXL770 At The World Congress On Insulin Resistance, Diabetes And Cardiovascular Diseases In Los Angeles 11/23/2015
F. Hoffmann-La Roche Ltd. (RHHBY) Release: Combination Of Bevacizumab And Lomustine With First Recurrence Of Glioblastoma Prolongs PFS But Not OS 11/23/2015
FDA Calls Merck KGaA (MKGAF.PK), Pfizer (PFE)'s Skin Cancer Drug Avelumab a Breakthrough 11/19/2015
Immodulon Therapeutics Release: Five-year Survival In Patients With Metastatic Melanoma Receiving IMM-101 11/19/2015
DelMar Pharma Reports First Quarter Fiscal Year 2016 Financial Results And Provides Corporate Update 11/17/2015
Allergan (AGN) Release: Positive Phase I/II Interim Data Of Bimatoprost Sustained-Release Implant For IOP Therapy In Glaucoma 11/16/2015
DelMar Pharma Presents Data Summarizing The Potential Of VAL-083 As A New Treatment Option For Resistant Cancers 11/13/2015
Albireo To Present A4250 Clinical Data At The 2015 American Association for Study of Liver Diseases Annual Meeting 11/12/2015
Allergan (AGN) Presents Data At The 2015 American Academy of Ophthalmology Annual Meeting In Las Vegas 11/12/2015
NeuroDerm (NDRM) Announces Streamlined U.S. Development Plan Following FDA Feedback On ND0612H And ND0612L For The Treatment Of Parkinson's Disease 11/11/2015
GenKyoTex S.A. 's GKT137831 Granted Orphan Drug Designation In The US And EU For The Treatment Of Systemic Sclerosis 11/11/2015
AstraZeneca PLC (AZN)'s Lupus Drug Anifrolumab Meets Goals in Mid-Stage Study 11/10/2015
DelMar Pharma To Present Updated Phase II Safety And Efficacy Data On VAL-083 In Refractory Glioblastoma Multiforme 11/10/2015
Teva (TEVA) Snags Breakthrough Therapy Designation from the FDA for Huntington's Disease Drug 11/9/2015
BiondVax Pharmaceuticals Announces Third Quarter 2015 Financial Results And Update 11/9/2015
AEterna Zentaris (AEZS) Reports Third Quarter Financial And Operating Results 11/6/2015
OncoGenex (OGXI) To Present At The Stifel 2015 Healthcare Conference 11/6/2015
ESSA Pharma Receives Health Canada Approval To Commence Clinical Development For EPI-506 11/5/2015
Oncolytics Biotech Inc. (ONC.TO) Announces 2015 Third Quarter Results 11/5/2015
ProNAi Therapeutics, Inc. Reports Third Quarter 2015 Results 11/5/2015
BioLineRx Ltd. Announces Positive Clinical Results From First Part Of Phase II Trial In R/R AML 11/5/2015
DelMar Pharma To Present At The SeeThruEquity Microcap Investor Forum On November 12, 2015 11/5/2015
Verona Pharma (VRP.L) Release: Completion Of Patient Enrolment In Two RPL554 Phase IIa Studies, Ahead Of Expected Timeline 11/5/2015
Zealand Pharma  (ZEAL.CO) Is Ready To Take Next Steps In A Diligent Growth Strategy For Accelerated Value Creation: From Peptide To Patient 11/4/2015
Janssen Sciences Ireland UC Release: First Investigational All Injectable Long Acting HIV Combination Regimen Study Results At 32 Weeks Announced 11/3/2015
ViiV Healthcare Announces Positive Headline Results From A Study Of Two Drug Injectable Regimen For HIV Maintenance Therapy 11/3/2015
Invion Limited Announces Full Enrollment Of NIH-Sponsored Asthma Trial 11/2/2015
Axovant (AXON) Announces RVT-101 Presentations At The Clinical Trials In Alzheimer's Disease (CTAD) Meeting 10/29/2015
Astellas (ALPMY) Inititaties Phase 3 Registration Trial Of gilteritinib (ASP2215) In Relapsed Or Refractory Acute Myeloid Leukemia Patients 10/28/2015
Transition Therapeutics (TTH.TO) Announces Presentation Of ELND005 Phase 2/3 Clinical Study Results At Clinical Trials In Alzheimer's Disease (CTAD) Conference 10/28/2015
Cellular Biomedicine Group (CBMG) Presented Phase IIa Results From CAR-T CD20 Immuno-Oncology Clinical Development Program for Advanced B-cell Non-Hodgkin Lymphoma 10/28/2015
BioBlast Pharma (ORPN) Announces Positive Interim Results From HOPEMD Phase II Clinical Study Of Cabaletta In Oculopharyngeal Muscular Dystrophy (OPMD) 10/27/2015
BioBlast Pharma (ORPN)To Host Conference Call & Webcast On Tuesday, October 27 To Discuss Interim Results From HOPEMD Phase II Clinical Study Of Cabaletta In Oculopharyngeal Muscular Dystrophy (OPMD) 10/27/2015
Twi Biotechnology Receives Notice Of Patent Allowance In Korea For Its Lead Drug Candidate AC-201 For The Indication Of Type II Diabetes 10/27/2015
Theravance Biopharma (TBPH) And Trek Therapeutics Announce Initiation Of Phase 2a Trial Of TD-6450, An NS5A Inhibitor To Treat Hepatitis C 10/27/2015
Prima Biomed (PRR.AX) Gains Belgian Regulatory Approval To Commence A Registration Phase Ilb Study Of IMP321 10/27/2015
Living Cell Technologies Ltd. Data Shows NTCELL Treatment Has Stopped The Progression Of Parkinsons 10/27/2015
Celgene (CELG) Release: Phase II Maintenance Data From Oral Ozanimod TOUCHSTONE Study In Ulcerative Colitis Presented At UEG Week 10/26/2015
Janssen-Cilag International NV (JNJ) Receives Positive CHMP Opinion Recommending EDURANT (rilpivirine) For The Treatment Of Adolescents Aged 12 To <18 Years With HIV-1 Infection 10/26/2015
Can-Fite BioPharma (CFBI) To Participate In BIO-Europe Partnering Conference On November 2-5, 2015 In Munich, Germany 10/26/2015
Shire (SHPG) Terminates Milestone Payments to Former Lumena Shareholders After Liver Drug Fails 10/23/2015
Aprea Presents Preliminary Clinical Phase Ib/II Results In Ovarian Cancer With APR-246 – A ‘First-In-Class’ Compound Reconverting Mutant To Wild-Type P53 Protein 10/23/2015
Hutchison China MediTech (Chi-Med) Release: Proof-Of-Concept Study Of Fruquintinib In Non-Small Cell Lung Cancer Triggers Milestone Payment 10/23/2015
VBL Therapeutics (VBLX) Presents Positive Data On VB-111 In Advanced Radioactive Iodine Refractory Differentiated Thyroid Cancer At The ITC 2015 Conference 10/22/2015
Onxeo Announces Data Demonstrating High Patient Compliance And Acceptability Of Validive For Treatment Of Severe Oral Mucositis 10/22/2015
DelMar Pharma Announces The Completion Of Enrollment In Its Phase II Expansion Study Of VAL-083 In Refractory Glioblastoma Multiforme 10/21/2015
BiondVax Pharmaceuticals Announces Successful Recruitment Of The First Participants In A Phase Ilb Clinical Trial In Europe With Its Universal Flu Vaccine: Multimeric M-001 10/21/2015
Foamix Pharmaceuticals, Ltd. (FOMX) Announces Enrollment Of First Patient In Phase II Clinical Trial Of FMX103 In Papulopustular Rosacea 10/20/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Phase 1b Study In Advanced Pancreatic Cancer 10/20/2015
Medivir (MVRBF) Announces That Janssen Pharmaceutical Has Started A Phase IIa Study To Evaluate The Effect Of Simeprevir In Combination With Odalasvir And AL-335 10/16/2015
Generex Biotechnology Corporation (GNBT) Announces Memorandum Of Understanding In Respect Of A Phase II Clinical Trial For The Antigen Express Prostate Cancer Vaccine 10/15/2015
Kuros Biosurgery AG To Present Positive kur-115 Pre Clinical Data For Interbody Spinal Fusion Treatment At The 2015 North American Spine Society 10/15/2015
RedHill Biopharma Provides Update On BEKINDA Ongoing Phase III Study For Gastroenteritis And Announces Planned Phase II Study For IBS-D 10/14/2015
Verona Pharma (VRP.L) Announces Start Of RPL554 Phase IIa Combination Study 10/14/2015
Hutchison China MediTech (Chi-Med) Release: Savolitinib Completes Enrolment For Phase II Clinical Trial In Papillary Renal Cell Carcinoma 10/13/2015
Can-Fite BioPharma (CFBI) Announces $4.8 Million Registered Direct Offering 10/13/2015
European Medicines Agency Grants Orphan Designation To Can-Fite BioPharma (CFBI)'s CF102 In The Treatment Of Liver Cancer 10/12/2015
Kuros Presents Results Of Phase IIB Study With KUR-111 At The 2015 Orthopaedic Trauma Association Annual Meeting 10/9/2015
Bionomics Limited (BNO.AX) Announces Extension Of Strategic Collaboration With Merck & Co. (MRK) For The Discovery And Development Of Novel Pain Medications 10/8/2015
BrainStorm Cell Therapeutics Inc. Announces Treatment Of Final Patient In US Multicenter Double Blinded Phase 2 ALS Trial 10/7/2015
Ascend Announces Patients With Nodular Basal Cell Carcinoma Receives First Dose Of ASN-002 In Phase 1/2a Study 10/7/2015
Invion Limited Successfully Completes Phase 2 Study Of INV102 (Nadolol) To Aid Smoking Cessation 10/5/2015
Pharmalink AB Raises SEK100m To Advance Nefecon Development As New Treatment For Kidney Disease 10/1/2015
OncoGenex (OGXI) Announces Completion Of Patient Enrollment In Borealis-2 Clinical Trial Evaluating Apatorsen In Relapsed Or Refractory Metastatic Bladder Cancer 9/30/2015
Phase II Trial Results Show Mesoblast (MSB.AX) Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure 9/30/2015
Important New Data From Teva (TEVA)'s TEV-48125 Phase IIB Migraine Program Published In Lancet Neurology In Back-To-Back Articles 9/30/2015
DelMar Pharmaceuticals To Present Data On The Promising Potential Of VAL-083 In The Treatment Of Pediatric Brain Tumors 9/29/2015
Can-Fite BioPharma (CFBI) To Present CF101 Psoriasis Data At Late Breaking Session Of The EADV Congress In Copenhagen On October 10, 2015 9/29/2015
Viralytics Ltd (VLA.AX) Presents Phase 2 Melanoma Extension Cohort Data, Updated CALM Study Survival And CAVATAK/Immune Checkpoint Combination Preclinical Data At 2015 European Cancer Congress 9/28/2015
AEterna Zentaris (AEZS)' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint In Men With Heavily Pretreated Castration And Taxane Resistant Prostate Cancer 9/28/2015
RXi Pharmaceuticals (RXII) Granted Patent In China For Lead Clinical Candidate RXI-109 9/28/2015
Neovacs SA Initiates Phase IIb Trial Of Ifna-Kinoid For The Treatment Of Lupus 9/24/2015
Positive Topline Results Announced From Phase I/II Trial In Sanfilippo B Syndrome Patients Using uniQure (QURE)'s Novel AAV5-Based Gene Therapy 9/21/2015
BioInvent (BOVNF) And The University of Pennsylvania Enhance Planned Clinical Study With BI-505 9/21/2015
FDA Grants Fast Track Designation To Can-Fite BioPharma (CFBI)'s CF102 In The Treatment Of Liver Cancer 9/17/2015
Infectious Disease Research Institute (IDRI) And Wellcome Trust Team For Tuberculosis Vaccine Trial In South Africa 9/17/2015
GW Pharma (GWPH) Surges on Positive Phase II Cannabis-Based Drug Study for Schizophrenia and Some Rare Diseases 9/16/2015
Benitec (BLT.AX) Initiates A Fourth Site In Hepatitis C Clinical Trial 9/16/2015
Aquinox (AQXP) Announces Closing Of $98.0 Million Public Offering Of Common Stock, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares 9/16/2015
Transition Therapeutics Inc. (TTH.TO) Announces Fiscal 2015 Financial Results 9/16/2015
MerLion Pharmaceuticals Pte Ltd To Present Detailed Phase 2 Data On Efficacy Of Finafloxacin In Complicated Urinary Tract Infections At International Congress Of Chemotherapy And Infection (ICC) 9/15/2015
Hutchison China MediTech (Chi-Med) Release: Fruquintinib Phase II Clinical Results In Colorectal Cancer To Be Presented At The 2015 European Cancer Congress 9/14/2015
PharmaMar Showcases New Data For YONDELIS And PM1183 In Soft Tissue Sarcoma And Solid Tumors At ECCO 2015 9/14/2015
Sun Biomedical (ASX: SBN) Initiates Phase II Clinical Trial Of Promising Combination Therapy For Chronic Kidney Disease 9/14/2015
BioBlast Pharma (ORPN) Granted Patent From USPTO For Cabaletta For The Treatment Of Spinocerebellar Ataxia (SCA) 9/14/2015
Amarantus Receives Orphan Drug Designation From The FDA For MANF For The Treatment Of Retinal Artery Occlusion 9/14/2015
Innapharma Fifth DSMB Meeting Of The EffiKIR Trial Recommends Continuation Without Modification 9/14/2015
TRANSGENE (ENX:TNG) Reports Financial Results For First Six Months Of 2015 9/11/2015
Merck KGaA (MKGAF.PK), Darmstadt, Germany And Pfizer (PFE) To Present Updates For Avelumab At The European Cancer Congress 2015 9/11/2015
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus XR Data To Be Presented At European Society Of Transplantation 9/10/2015
Celsion (CLSN) Updates Clinical Trial Data and Slashes 20% of Workforce 9/9/2015
Endo Pharmaceuticals (ENDP) And BioDelivery Sciences International (BDSI) Present New Data On Investigational Product Buprenorphine Hcl Buccal Film For Chronic Pain Management 9/9/2015
RedHill Biopharma Ltd. (RDHL) Announces $2 Million National Cancer Institute Grant For YELIVA(TM) (ABC294640) Phase II Study For Multiple Myeloma 9/9/2015
Immunocore's IMCgp100 Accepted For Adaptive Pathway Pilot Programme 9/9/2015
DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data On VAL-083 In Refractory Glioblastoma Multiforme At GBM2015 9/9/2015
IAVI And CureVac Partner To Accelerate Development And Testing Of AIDS Vaccine Candidates 9/9/2015
Valeant (VRX) And Progenics Pharmaceuticals, Inc. (PGNX) Announce FDA Acceptance Of NDA Submission For Oral RELISTOR 9/8/2015
Helsinn Group Signs Exclusive Agreement With Bial For Distribution And Licence Of Anamorelin In Spain, Portugal, Angola And Mozambique 9/8/2015
ORYZON Genomics Achieves Milestone In The Clinical Development Of ORY-1001 9/8/2015
TRANSGENE (ENX:TNG) Announces Final Overall Survival Data From Phase IIb TIME Trial With TG4010 Immunotherapy In Non-Small Cell Lung Cancer 9/8/2015
Hutchison China MediTech (Chi-Med) Release: Second Proof-Of-Concept Trial Of Fruquintinib Achieves Its Primary Endpoint 9/4/2015
DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results And Provides Corporate Update 9/4/2015
Oramed (ORMP) To Present At The Rodman & Renshaw Global Investment Conference 9/4/2015
Chugai Pharmaceutical Co., Ltd. (Japan)'s Bispecific Antibody "ACE910" For The Treatment Of Hemophilia A Designated As A Breakthrough Therapy By The FDA 9/4/2015
Helsinn Group Signs Exclusive Agreement With Munipharma For The Distribution And Licence Of Anamorelin In Switzerland And Liechtenstein 9/3/2015
Glenmark Pharmaceuticals's Novel Monoclonal Antibody GBR 830 To Enter Phase 2 Clinical Studies In Atopic Dermatitis And Celiac Disease In US And Europe 9/3/2015
Atopix Appoints Dr Andrew Zambanini As Chief Medical Officer 9/3/2015
Can-Fite BioPharma (CFBI) To Present At Rodman & Renshaw 17th Annual Global Investment Conference On September 9, 2015 9/1/2015
Neovacs SA Receives First Regulatory Approvals For A Phase IIb Trial Of Ifna-Kinoid In Lupus 9/1/2015
XTL Biopharmaceuticals Ltd. (XTLB) Reports Second Quarter 2015 Results 9/1/2015
MicuRx Pharmaceuticals Says Novel Antibiotic Passes China Phase II Test 9/1/2015
ERYtech Pharma Appoints Eric Soyer As Chief Financial And Chief Operating Officer 9/1/2015
Ascletis, Inc. Phase II Clinical Trial Of Its Interferon-Free HCV Regimen In Taiwan 8/31/2015
MicuRx Pharmaceuticals Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 8/31/2015
Allergan (AGN) Successfully Completes Naurex Acquisition 8/31/2015
Oncolytics Biotech Inc. (ONC.TO) Collaborators To Present Survival Data From REO 016 Study In Non-Small Cell Lung Cancer 8/27/2015
iCo Therapeutics Inc. Announces Second Quarter 2015 Financial Results 8/27/2015
DelMar Pharmaceuticals To Announce Fiscal 2015 Year-End Financial Results On September 4, 2015 8/27/2015
ORYZON To Present At Rodman & Renshaw 17th Annual Global Investment Conference 8/27/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Completion Of Enrollment In Randomized Phase II Non-Small Cell Lung Cancer Study 8/26/2015
XTL Biopharmaceuticals Ltd. (XTLB) Announces Publication Of Results Of Phase 2 Study On Hcdr1 (Edratide) In Patients With Active Systemic Lupus Erythematosus (SLE) In Lupus Science & Medicine 8/26/2015
Nordic Nanovector: Results For The Second Quarter And Half Year 2015 8/26/2015
Allergan (AGN) And Gedeon Richter Ltd. (RIG2.F) To Present Data From Cariprazine Trials At European College Of Neuropsychopharmacology (ECNP) Annual Meeting In Amsterdam 8/25/2015
Ascendis Pharma A/S Reports Second Quarter 2015 Financial Results 8/25/2015
DelMar Pharmaceuticals To Present At The 17th Annual Rodman & Renshaw Global Investment Conference On September 9, 2015 8/25/2015
DelMar Pharmaceuticals To Present VAL-083 Lung Cancer Clinical Strategy At The 16th World Conference On Lung Cancer 8/24/2015
NMT Pharmaceuticals Singapore Announces Signing Of Letter Of Intent With CAO Pharmacueticals USA In Licensing And Development Of Anti-Cancer Drug CZ-48 8/24/2015
DelMar Pharmaceuticals Completes $2.6 Million Registered Direct Offering 8/20/2015
PharmaMar Announces License Agreement With Specialised Therapeutics Australia Pty For APLIDIN (plitidepsin) In Oncology 8/20/2015
BioLineRx Ltd. Reports Second Quarter 2015 Financial Results 8/20/2015
Vernalis PLC (VNLPY.PK) Completes Investment In Its NCE Development Pipeline 8/20/2015
CytoDyn Release: First Self-Injectable HIV Antibody: 98% Success Rate In Phase 2b Clinical Trial, Could Be Commercial 8/18/2015
Relmada Therapeutics Receives Health Canada Clearance To Commence Multiple Ascending Dose Study With Promising NMDA Receptor Antagonist 8/17/2015
DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding From NRC-IRAP To Support Expanded Research Program With Lead Product Candidate VAL-083 8/17/2015
Invion Limited Completes Clinical Trial Of INV103 (ala-Cpn10) In Lupus Patients 8/17/2015
BioLineRx Ltd. Announces Initiation Of Phase 2b Trial For Novel AML Consolidation Treatment 8/17/2015
OncoGenex Pharmaceuticals Inc. (OGXI) Reports Financial Results For Second Quarter 2015 8/14/2015
Sophiris Bio Inc. (SPHS) Reports Second Quarter Financial Results 8/14/2015



//-->